These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19485902)

  • 21. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
    Morris TA
    Clin Chest Med; 2010 Dec; 31(4):707-18. PubMed ID: 21047577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 27. Brave new world: the current and future use of novel anticoagulants.
    Spyropoulos AC
    Thromb Res; 2008; 123 Suppl 1():S29-35. PubMed ID: 18835010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New oral anticoagulants for acute venous thromboembolism.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):3-4. PubMed ID: 24419296
    [No Abstract]   [Full Text] [Related]  

  • 30. New anticoagulants: focus on venous thromboembolism.
    Gómez-Outes A; Lecumberri R; Pozo C; Rocha E
    Curr Vasc Pharmacol; 2009 Jul; 7(3):309-29. PubMed ID: 19601856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New anticoagulants for treatment of venous thromboembolism.
    Gross PL; Weitz JI
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):380-6. PubMed ID: 18296593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New oral anticoagulants in the treatment of venous thromboembolic disease].
    Calvo Romero JM; Lima Rodríguez EM
    Semergen; 2013 Apr; 39(3):146-9. PubMed ID: 23540987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential of new anticoagulants in patients with cancer.
    Weitz JI
    Thromb Res; 2010 Apr; 125 Suppl 2():S30-5. PubMed ID: 20434001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E
    MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
    [No Abstract]   [Full Text] [Related]  

  • 37. The novel anticoagulants: the surgeons' prospective.
    Shamoun FE; Martin EN; Money SR
    Surgery; 2013 Mar; 153(3):303-7. PubMed ID: 23218887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and adjusted indirect comparison of oral anticoagulants.
    Cui J; Wu B; Liu C; Li Z
    Orthopedics; 2014 Nov; 37(11):763-71. PubMed ID: 25361361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target-specific oral anticoagulants: practice issues for the clinician.
    Plitt A; Giugliano RP
    Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.